Lemonex

Pipeline

Lemonex is developing cancer immunotherapeutics, antibody therapeutics and gene therapeutics based on next-generation innovative modular drug delivery technology and biosensor technology. We especially focus on the development of therapeutics to treat cancers, intractable diseases

DDS Platform

Platform	Research	Pre-Clinical	Manufacturing permission	Item approval
DegradaBALL	●	●	●	●

Pipeline

Pipeline	Component	Indication	Research	Pre-Clinical	Clinical Phase
Pipeline	Component	Indication	Research	Pre-Clinical	Ⅰ	Ⅱ	Ⅱ
LEM-S401	siRNA-DegradaBALL	Hypertrophic Scar & Keloid	●	●	●
LEM-mR203	mRNA-DegradaBALL	COVID-19	●	●	○
LEM-S403	Dual-Acting RNA-DegradaBALL	Solid Cancer	●	●
BALLkine-2	Cytokine	Solid Cancer	●	●

Lemonex Inc. | Address : DM Tower 1F, 33,55 , Hyoryeong-ro, Seocho-gu, Seoul 06665, Korea
CEO : Cheolhee Won, CTO : Dal-Hee Min | Tel : +82-2-525-7797 | Fax : +82-2-525-7798 | E-mail : info@lemonexbio.com
Copyright (c) 2018 Lemonex Inc., All rights reserved.